IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation

IceCure Medical (ICCM) announced the successful treatment of the first patient in its ChoICE post-marketing study for breast cancer cryoablation. The study, led by West Cancer Center in Tennessee, aims to enroll 400 patients across 30 U.S. sites. The company's ProSense® system is FDA-cleared for specific breast cancer treatments. IceCure expects the study to support broader adoption of its cryoablation technology.

Original reporting
Published Oct 27, 2026, 12:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 12:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation — source image
Decision brief

The 30-second read

$ICCMBullishMed
01

Why it matters

The announcement provides the first concrete data point of the study’s execution, signaling progress toward broader commercial adoption.

02

Market read

First patient treatment is a material milestone for a micro‑cap biotech, likely generating short‑term buying interest.

03

What to watch

Potential regulatory scrutiny or reimbursement challenges could dampen long‑term upside.

Relevance 7/10Novelty 8/10Timing: immediate

Background

IceCure Medical (NASDAQ: ICCM) develops liquid‑nitrogen cryoablation systems. The ChoICE study will enroll ~400 patients across up to 30 US sites to generate real‑world data on its FDA‑cleared ProSense® system for low‑risk breast cancer.

Company-level read

Ticker impact

$ICCMBullishHigh confidence
Context

IceCure Medical announced the first patient treatment in its ChoICE post‑marketing study for breast cancer cryoablation.

Expected impact

likely upward pressure as the market prices in the successful start of the study

Evidence & confidence

First‑in‑human treatment is a material, novel event for a micro‑cap biotech; investors typically react positively to clinical progress.

Market effects

May increase interest in cryoablation technologies and related med‑tech stocks.

Limited to US biotech sector; no broader regional effect.

Low; relevance confined to niche oncology device market.

Counterpoint

If the study fails to enroll or shows limited efficacy, the initial hype could reverse quickly.

Key entities

  • IceCure Medical Ltd.

    Developer of the ProSense® cryoablation system.

  • West Cancer Center & Research Institute

    Site of the first patient treatment.

Related articles

$ICCMMedAI 8/10

A breast cancer study treats its first patient by freezing a tumor

IceCure Medical (ICCM) treated the first patient in its ChoICE Study at West Cancer Center, using its ProSense® cryoablation system for breast cancer. The study aims to enroll 400 patients across 30 U.S. sites, generating real-world data. ProSense® is FDA-cleared for specific breast cancer treatments. IceCure develops cryoablation therapy systems for tumor destruction.

$ICCMHighAI 8/10

IceCure Medical Wins Regulatory Approval To Market ProSense In China

IceCure Medical (ICCM) received regulatory approval from China's NMPA for its ProSense cryoablation system, expanding its global market. The device, already cleared in the U.S. and Europe, is used to treat tumors in breast, kidney, bone, and lung. The approval was supported by clinical data, and the company plans to accelerate commercialization in China. ICCM's stock is up 1.42% to $2.14.

$ICCMMed

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

IceCure Medical (ICCM) received IRB approval from West Cancer Center for its ChoICE study on ProSense® cryoablation for low-risk breast cancer. The study, expected to enroll patients soon, aims to gather real-world data on the treatment. ProSense® is FDA-approved for women 70+ with low-risk tumors. The study will involve 30 sites and 400 patients, expanding access to cryoablation.

$ICCMMed

IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript

IceCure Medical (ICCM) reported $1.8M in H1 2026 revenue, up 45% YoY. U.S. revenue grew 64% post-FDA clearance. Gross profit rose 57% to $548K, but net loss widened to $8.8M. Cash increased to $12M after $8.5M Q2 financing. Management highlighted growth in system and disposable probe sales, U.S. expansion, and the CHOICE study.